24/7 Market News Snapshot 12 May, 2025 – Abeona Therapeutics Inc. Common Stock (NASDAQ:ABEO)

May 12, 2025

DENVER, Colo., 12 May, 2025 (www.247marketnews.com) – (NASDAQ:ABEO) are discussed in this article.
Abeona Therapeutics Inc. (ABEO) has demonstrated significant momentum in the financial markets, opening at $5.80 and experiencing an impressive gain of 10.63% to reach a current trading price of $5.83. This bullish trend reflects increasing investor confidence, illustrated by a trading volume of 3.72 million shares, highlighting substantial interest from both institutional and retail investors. Analysts suggest that maintaining this upward trajectory could lead to a test of resistance levels, making it critical for traders to monitor support levels closely for effective risk management during this active phase.

In a remarkable strategic development, Abeona has finalized a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $155 million. This vital transaction is expected to close imminently, following the recent U.S. Food and Drug Administration (FDA) approval of Abeona’s novel therapy, ZEVASKYN™ (prademagene zamikeracel), on April 28, 2025. Joe Vazzano, Chief Financial Officer of Abeona, emphasized that this sale enhances the company’s financial standing, allowing operational funding for over two years without the need for new capital beyond ZEVASKYN’s sales.

ZEVASKYN, which is poised to initiate patient treatments in the third quarter of 2025, is projected to bring the company to profitability by early 2026. The PRV is awarded to expedite treatments for rare pediatric conditions, reinforcing Abeona’s commitment to addressing critical healthcare challenges. This transaction awaits routine closing conditions, particularly the regulatory review under the Hart-Scott-Rodino Antitrust Improvements Act.

As a leader in biopharmaceutical innovation, Abeona Therapeutics focuses on developing transformative cell and gene therapies for severe diseases, with ZEVASKYN representing a significant breakthrough for patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). The company continues its dedication to advancing therapies that meet profound unmet healthcare needs, particularly in the realm of ophthalmic disorders.

Related news for (ABEO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.